Japan lays out topics for price reform discussions
This article was originally published in Scrip
The regulatory authorities in Japan have begun identifying the major drug reimbursement pricing topics for discussion ahead of the next regular biennial price revision in the country in April 2012.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.